Database Query Results : , , SMAD2

SMAD2, SMAD family member 2: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG
SMAD2 (SMAD family member 2) is a protein that plays a crucial role in the transforming growth factor-beta (TGF-β) signaling pathway, which is involved in various cellular processes, including cell growth, differentiation, and apoptosis.
In some cancers, SMAD2 functions as a tumor suppressor. TGF-β signaling can inhibit cell proliferation and promote apoptosis in normal and early-stage cancer cells. In this context, SMAD2 helps to mediate these effects, and its loss or mutation can contribute to tumor progression. Conversely, in advanced cancers, TGF-β signaling can promote tumor progression and metastasis. In these cases, SMAD2 may contribute to the epithelial-to-mesenchymal transition (EMT), a process that allows cancer cells to acquire migratory and invasive properties. This dual role can make targeting the TGF-β/SMAD2 pathway challenging in cancer therapy.
Scientific Papers found: Click to Expand⟱
1124- ALA,    Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells
- in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, HTH-83 - in-vitro, Thyroid, CAL-62 - in-vitro, Thyroid, FTC-133 - in-vivo, NA, NA
TumCP↓, AMPK↑, mTOR↓, TumCMig↓, TumCI↓, EMT↓, E-cadherin↑, β-catenin/ZEB1↓, Vim↓, Snail↓, Twist↓, TGF-β↓, p‑SMAD2↓, TumCG↓,
1093- And,    Andrographolide attenuates epithelial‐mesenchymal transition induced by TGF‐β1 in alveolar epithelial cells
- in-vitro, Lung, A549
TGF-β↓, TumCMig↓, MMP2↓, MMP9↓, ECM/TCF↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓, p‑ERK↓, ROS↓, NOX4↓, SOD2↑, SIRT1↑, FOXO3↑,
238- Api,    Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, C4-2B
VEGF↓, TGF-β↓, Src↓, FAK↓, Akt↓, SMAD2↓, SMAD3↓,
1181- Ash,    Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCMig↓, TumCI↓, EMT↓, p‑SMAD2↓, p‑SMAD3↓, p‑NF-kB↓,
1173- Ash,    Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling
- in-vitro, EC, K1 - in-vitro, Nor, THESCs
TumCP↓, *toxicity↓, Apoptosis↑, TumCCA↑, TumCMig↓, TumCI↓, p‑SMAD2↓, TGF-β↓, *toxicity↓,
2763- BetA,    Betulinic Acid Inhibits the Stemness of Gastric Cancer Cells by Regulating the GRP78-TGF-β1 Signaling Pathway and Macrophage Polarization
- in-vitro, GC, NA
GRP78/BiP↓, TGF-β↓, ChemoSen↑, CSCs↓, SMAD2↓, SMAD3↓, OCT4↓,
447- CUR,  OXA,    Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway
- vitro+vivo, CRC, HCT116
p‑p65↓, Bcl-2↓, Casp3↑, EMT↓, p‑SMAD2↓, p‑SMAD3↓, N-cadherin↓, TGF-β↓, E-cadherin↑, TumVol↓, TumCMig↓,
1110- EA,  GEM,    Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
- vitro+vivo, Bladder, NA
TGF-β↓, SMAD2↓, SMAD3↓, SMAD4↓,
1072- EGCG,    Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways
- in-vitro, Thyroid, 8505C
EMT↓, TumCI↓, TumCMig↓, TGF-β↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓,
817- GAR,    Garcinol inhibits esophageal cancer metastasis by suppressing the p300 and TGF-β1 signaling pathways
- vitro+vivo, SCC, KYSE150 - vitro+vivo, SCC, KYSE450
HATs↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, CBP↓, p300↓, TGF-β↓, Ki-67↓, SMAD2↓, SMAD3↓,
1117- Gb,    Ginkgobiloba leaf extract mitigates cisplatin-induced chronic renal interstitial fibrosis by inhibiting the epithelial-mesenchymal transition of renal tubular epithelial cells mediated by the Smad3/TGF-β1 and Smad3/p38 MAPK pathways
- vitro+vivo, Kidney, HK-2
α-SMA↓, COL1↓, TGF-β↓, SMAD2↓, SMAD3↓, p‑SMAD2↓, p‑SMAD3↓, p38↓, p‑p38↓, Vim↓, TIMP1↓, CTGF↓, E-cadherin↑, MMP1:TIMP1↑,
1118- Ge,    Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF- β Signaling Pathway
- in-vitro, Bladder, T24 - in-vitro, Bladder, 5637
TumCMig↓, TumCI↓, MMP2↓, MMP9↓, EMT↓, N-cadherin↓, Vim↓, Slug↓, E-cadherin↑, ZO-1↑, p‑SMAD2↓, p‑SMAD3↓, p‑Akt↓, p‑ERK↓, p‑p38↓,
2882- HNK,    Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling
- in-vitro, PC, PANC1
TumCI↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, Snail↓, Slug↓, Rho↓, ROCK1↓,
2884- HNK,    Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP
- in-vitro, Lung, A549 - in-vitro, Lung, H460
EMT↓, cFLIP↓, N-cadherin↓, Snail↓, p‑SMAD2↓, p‑SMAD3↓, IKKα↑, TumCMig↓,
4632- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, SUM159
CSCs↓, TumCMig↓, TumCI↓, β-catenin/ZEB1↓, Wnt↓, p‑LRP6↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, SMAD2↓, SMAD3↓, TGF-β↓,
1266- LE,    Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
HMGB1↓, EMT↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓,
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF-7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
1059- PI,    Piperine Inhibits TGF-β Signaling Pathways and Disrupts EMT-Related Events in Human Lung Adenocarcinoma Cells
- in-vitro, Lung, A549 - in-vitro, BC, MDA-MB-231 - in-vitro, Liver, HepG2
EMT↓, p‑ERK↓, p‑SMAD2↓,
3604- QC,    Quercetin enrich diet during the early-middle not middle-late stage of alzheimer’s disease ameliorates cognitive dysfunction
- in-vivo, AD, NA
*cognitive↑, *Aβ↓, *neuroP↑, *BACE↓, *p‑SMAD2↓, *p‑STAT3↓, *SPARC↓,
878- RES,    Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression
- vitro+vivo, CRC, LoVo
TumMeta↓, E-cadherin↑, Vim↓, TGF-β↓, SMAD2↓, EMT↓, SMAD3↓,
3098- RES,    Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers
- Review, Var, NA
NOTCH2↓, Wnt↓, β-catenin/ZEB1↓, p‑SMAD2↓, p‑SMAD3↓, PTCH1↓, Smo↓, Gli1↓, E-cadherin↑, NOTCH⇅, TAC?, NKG2D↑, DR4↑, survivin↓, DR5↑, BAX↑, p27↑, cycD1/CCND1↓, Bcl-2↓, STAT3↓, STAT5↓, JAK↓, DNAdam↑, γH2AX↑,
3092- RES,    Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action
- Review, BC, MDA-MB-231 - Review, BC, MCF-7
TumCP↓, tumCV↓, TumCI↓, TumMeta↓, *antiOx↑, *cardioP↑, *Inflam↓, *neuroP↑, *Keap1↓, *NRF2↑, *ROS↓, p62↓, IL1β↓, CRP↓, VEGF↓, Bcl-2↓, MMP2↓, MMP9↓, FOXO4↓, POLD1↓, CK2↓, MMP↓, ROS↑, Apoptosis↑, TumCCA↑, Beclin-1↓, Ki-67↓, ATP↓, GlutMet↓, PFK↓, TGF-β↓, SMAD2↓, SMAD3↓, Vim?, Snail↓, Slug↓, E-cadherin↑, EMT↓, Zeb1↓, Fibronectin↓, IGF-1↓, PI3K↓, Akt↓, HO-1↑, eff↑, PD-1↓, CD8+↑, Th1 response↑, CSCs↓, RadioS↑, SIRT1↑, Hif1a↓, mTOR↓,
1134- SANG,    Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
Hif1a↓, EMT↓, Snail↓, PI3K↓, Akt↓, SMAD2↓, SMAD3↓,
1133- SM,    Salvianolic Acid A, a Component of Salvia miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of HPAECs Induced by Hypoxia
- in-vitro, Nor, HPAECs
*ROS↓, *p‑Smad1↑, *p‑SMAD5↑, *SMAD2↓, *SMAD3↓, *p‑ERK↓, *p‑Cofilin↓,
1138- TQ,    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumMeta↓, EMT↓, E-cadherin↑, Vim↓, Slug↓, TGF-β↓, SMAD2↓, SMAD3↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 26

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HO-1↑, 1,   NOX4↓, 1,   ROS↓, 1,   ROS↑, 1,   SOD2↑, 1,   TAC?, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   GlutMet↓, 1,   PFK↓, 1,   POLD1↓, 1,   SIRT1↑, 2,  

Cell Death ⓘ

Akt↓, 3,   p‑Akt↓, 1,   Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 3,   Casp3↑, 1,   CBP↓, 1,   cFLIP↓, 1,   CK2↓, 1,   DR4↑, 1,   DR5↑, 1,   p27↑, 1,   p38↓, 1,   p‑p38↓, 2,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

HATs↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

GRP78/BiP↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,   p62↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 2,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 3,   EMT↓, 15,   p‑ERK↓, 3,   FOXO3↑, 1,   FOXO4↓, 1,   Gli1↓, 1,   IGF-1↓, 1,   LRP6↓, 1,   p‑LRP6↓, 1,   mTOR↓, 2,   NOTCH⇅, 1,   NOTCH2↓, 1,   OCT4↓, 1,   p300↓, 1,   PI3K↓, 2,   PTCH1↓, 1,   Smo↓, 1,   Src↓, 1,   STAT3↓, 1,   STAT5↓, 1,   TumCG↓, 1,   Wnt↓, 2,  

Migration ⓘ

COL1↓, 1,   CTGF↓, 1,   E-cadherin↑, 10,   FAK↓, 1,   Fibronectin↓, 1,   Ki-67↓, 2,   MMP1:TIMP1↑, 1,   MMP2↓, 3,   MMP9↓, 3,   N-cadherin↓, 5,   Rho↓, 1,   ROCK1↓, 1,   Slug↓, 6,   SMAD2↓, 10,   p‑SMAD2↓, 15,   SMAD3↓, 10,   p‑SMAD3↓, 12,   SMAD4↓, 3,   Snail↓, 6,   TGF-β↓, 16,   TIMP1↓, 1,   TumCI↓, 11,   TumCMig↓, 14,   TumCP↓, 5,   TumMeta↓, 3,   Twist↓, 2,   Vim?, 1,   Vim↓, 9,   Zeb1↓, 2,   ZO-1↑, 1,   α-SMA↓, 1,   β-catenin/ZEB1↓, 4,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   ECM/TCF↓, 1,   Hif1a↓, 2,   VEGF↓, 3,  

Immune & Inflammatory Signaling ⓘ

CRP↓, 1,   HMGB1↓, 1,   IKKα↑, 1,   IL1β↓, 1,   JAK↓, 1,   LIF↑, 1,   p‑NF-kB↓, 1,   p‑p65↓, 1,   PD-1↓, 1,   Th1 response↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   Ki-67↓, 2,  

Functional Outcomes ⓘ

NKG2D↑, 1,   TumVol↓, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 114

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Keap1↓, 1,   NRF2↑, 1,   ROS↓, 2,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,   p‑STAT3↓, 1,  

Migration ⓘ

p‑Cofilin↓, 1,   p‑Smad1↑, 1,   SMAD2↓, 1,   p‑SMAD2↓, 1,   SMAD3↓, 1,   p‑SMAD5↑, 1,   SPARC↓, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   BACE↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   cognitive↑, 1,   neuroP↑, 2,   toxicity↓, 2,   toxicity∅, 1,  
Total Targets: 21

Scientific Paper Hit Count for: SMAD2, SMAD family member 2
3 Resveratrol
2 Ashwagandha(Withaferin A)
2 Honokiol
1 Alpha-Lipoic-Acid
1 Andrographis
1 Apigenin (mainly Parsley)
1 Betulinic acid
1 Curcumin
1 Oxaliplatin
1 Ellagic acid
1 Gemcitabine (Gemzar)
1 EGCG (Epigallocatechin Gallate)
1 Garcinol
1 Ginkgo biloba
1 Grapeseed extract
1 HydroxyTyrosol
1 Licorice
1 Magnolol
1 Magnetic Fields
1 Piperine
1 Quercetin
1 Sanguinarine
1 Salvia miltiorrhiza
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:283  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page